Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 147,934 Shares of Company Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 147,934 shares of the business’s stock in a transaction on Friday, October 23rd. The stock was sold at an average price of $30.59, for a total transaction of $4,525,301.06. Following the transaction, the insider directly owned 169,753 shares in the company, valued at $5,192,744.27. This trade represents a 46.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total transaction of $4,044,632.48.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total transaction of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total transaction of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total transaction of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.
• On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total transaction of $3,674.72.
• On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Price Performance

NASDAQ ALMR opened at $31.93 on Wednesday. The company has a 50-day moving average of $30.73. Alamar Biosciences, Inc. has a twelve month low of $18.84 and a twelve month high of $39.61.

Alamar Biosciences (NASDAQ:ALMR) last released its earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $29.43 million for the quarter. As a group, sell-side analysts anticipate that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ALMR shares. Stifel Nicolaus lifted their price objective on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. upped their target price on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. TD Cowen reaffirmed a “buy” rating on shares of Alamar Biosciences in a research report on Wednesday, July 15th. Finally, Weiss Ratings downgraded shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Alamar Biosciences currently has an average rating of “Hold” and an average target price of $31.80.

Institutional Trading of Alamar Biosciences

Several institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC acquired a new position in Alamar Biosciences in the second quarter worth about $283,000. State Street Corp bought a new position in Alamar Biosciences during the second quarter worth about $3,930,000. Wellington Management Group LLP bought a new position in Alamar Biosciences during the second quarter worth about $12,407,000. Finally, Braidwell LP acquired a new stake in Alamar Biosciences during the second quarter valued at approximately $29,365,000.

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.